Revolutionizing Healthcare with Early Disease Detection
Quanterix, a company developing technology designed to enable earlier disease detection, made its market debut on Thursday. Shares of the company surged after pricing at $15 a share, and opening at $16.25 a share. Kevin Hrusovsky, CEO of Quanterix, was with us to discuss how the company plans to revolutionize healthcare.
The fourth-leading cause of death is drug side effects, and drugs only work half the time, says Hrusovsky. He believes that if you can personalize the drugs, you have an opportunity to improve the whole pharmaceutical industry.
Quanterix is developing technology that will digitize how they see into blood, and help to see disease long before there are symptoms. Rocket science is being deployed into the blood, says Hrusovsky. He says that if you can see biomarkers and incorporate into fitbits, it can really help improve health.
Blame geography for the U.S. getting hit by stronger, costlier, more varied and frequent extreme weather than anywhere on the planet, several experts said. But that's only part of it.
Residents across a wide swath of the U.S. raced Sunday to assess the destruction from fierce storms that spawned possibly dozens of tornadoes from the South and the Midwest into the Northeast.
The U.S. Food and Drug Administration has approved selling overdose antidote naloxone over-the-counter, marking the first time a opioid treatment drug will be available without a prescription.
Millions of Americans could lose access to Medicaid on April 1, and Joe Dunn, senior vice president of public policy at the National Association of Community Health Centers, joined Cheddar News' anchor Shannon LaNier to discuss what this means for public health.
One third of Americans don't have access to primary care providers in their communities, according to a study from the National Association of Community Health Centers published last month.
Neuralink, Elon Musk's brain implant venture, is reaching out to major U.S. neurosurgery centers to potentially begin testing its devices on humans, according to a Reuters report.
